Düsseldorf-Jülich Symposium on Neurodegenera7ve Diseases 2017 Bildquelle: Fotolia

Prof. Dieter Willbold talks with Summer Park of PharmaVentures at Biotech and Money Investival, London in 2017.

News & Events:

Team Assistant (m/w/d)
Team Assistant (m/w/d)

January 28, 2022
Staff Scientist Cellular Assays 
Staff Scientist Cellular Assays 

January 28, 2022
Staff Scientist in vitro ADME
Staff Scientist in vitro ADME

January 28, 2022
TIDES Boston May, 2022
TIDES Boston May, 2022

December 14, 2021
Funding from The Michael J. Fox Foundation
Funding from The Michael J. Fox Foundation

February 24, 2021
Priavoid closes financing round
Priavoid closes financing round

February 12, 2021
Sprunginnovationsprojekt geht neue Wege in der Alzheimer-Therapie
Sprunginnovationsprojekt geht neue Wege in der Alzheimer-Therapie

February 11, 2021
Alzheimer´s Research: Important Milestone for PRI-002
Alzheimer´s Research: Important Milestone for PRI-002

February 4, 2021
Nobel Prize winner Stanley Prusiner joins Priavoid’s supervisory board
Nobel Prize winner Stanley Prusiner joins Priavoid’s supervisory board

December 9, 2020
New CEO of Priavoid
New CEO of Priavoid

September 2, 2020
Priavoid Headquarters at LSC Düsseldorf
Priavoid Headquarters at LSC Düsseldorf

March 6, 2020
Seed Investment
Seed Investment

May 6, 2019
Prof. Willbold´s interview with PharmaVentures
Prof. Willbold´s interview with PharmaVentures

January 23, 2018
Clinical trial with PRI-002
Clinical trial with PRI-002

May 31, 2017